$1.41
5.07% today
Nasdaq, Apr 03, 06:19 pm CET
ISIN
US74017N1054
Symbol
PGEN
Sector
Industry

Precigen Inc Stock price

$1.48
-0.19 11.38% 1M
+0.51 53.23% 6M
+0.36 32.14% YTD
+0.09 6.47% 1Y
-1.05 41.50% 3Y
-1.38 48.25% 5Y
-38.09 96.26% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.05 3.14%
ISIN
US74017N1054
Symbol
PGEN
Sector
Industry

Key metrics

Market capitalization $435.18m
Enterprise Value $370.99m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 94.40
P/S ratio (TTM) P/S ratio 110.73
P/B ratio (TTM) P/B ratio 11.25
Revenue growth (TTM) Revenue growth -36.95%
Revenue (TTM) Revenue $3.93m
EBIT (operating result TTM) EBIT $-94.71m
Free Cash Flow (TTM) Free Cash Flow $-76.76m
Cash position $97.91m
EPS (TTM) EPS $-0.48
P/E forward negative
P/S forward 39.12
EV/Sales forward 33.35
Short interest 11.73%
Show more

Is Precigen Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Precigen Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Precigen Inc forecast:

3x Buy
75%
1x Sell
25%

Analyst Opinions

4 Analysts have issued a Precigen Inc forecast:

Buy
75%
Sell
25%

Financial data from Precigen Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
3.93 3.93
37% 37%
100%
- Direct Costs 6.91 6.91
30% 30%
176%
-2.99 -2.99
18% 18%
-76%
- Selling and Administrative Expenses 36 36
20% 20%
915%
- Research and Development Expense 51 51
5% 5%
1,304%
-90 -90
10% 10%
-2,295%
- Depreciation and Amortization 4.53 4.53
32% 32%
115%
EBIT (Operating Income) EBIT -95 -95
7% 7%
-2,410%
Net Profit -126 -126
32% 32%
-3,212%

In millions USD.

Don't miss a Thing! We will send you all news about Precigen Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Precigen Inc Stock News

Neutral
Seeking Alpha
15 days ago
Precigen, Inc. (NASDAQ:PGEN ) Q4 2024 Earnings Conference Call March 19, 2025 4:30 PM ET Company Participants Steven Harasym - IR Helen Sabzevari - President and CEO Rutul Shah - COO Phil Tennant - CCO Harry Thomasian - CFO Conference Call Participants Jason Butler - Citizens Carolina Ibanez Ventoso - Stifel Swayampakula Ramakanth - H.C. Wainwright Jennifer Kim - Cantor Brian Cheng - JPMorgan O...
Neutral
PRNewsWire
15 days ago
FDA granted priority review to Company's BLA for PRGN-2012 for the treatment of adults with recurrent respiratory papillomatosis and set PDUFA target action date for August 27, 2025 Results from pivotal clinical study of PRGN-2012 were published in The Lancet Respiratory Medicine PRGN-2012 treatment demonstrated durable complete responses with median duration of response of two years, with some...
Neutral
PRNewsWire
21 days ago
GERMANTOWN, Md. , March 13, 2025 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release full year 2024 financial results and provide business updates on Wednesday, March 19, 2025.
More Precigen Inc News

Company Profile

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. The firm focuses on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals. It operates through the following segments: PGEN Therapeutics, ActoBio, MBP Titan, Trans Ova and All Other. The PGEN Therapeutics segment is advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders and infectious diseases. The ActoBio segment involves in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The MBP Titan segment comprises of Methane Bioconversion Platform, and associated technologies, personnel, and facilities The Trans Ova segment includes provides advanced reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Head office United States
CEO Helen Sabzevari
Employees 143
Founded 1998
Website www.precigen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today